Evidence map›Paper›PMID 28411309›Full record

ArticlePathology oncology research : POR2018

Calreticulin Mutations in Bulgarian MPN Patients.

Ivan Pavlov, Evgueniy Hadjiev, Tzvetan Alaikov, Sylva Spassova, Angel Stoimenov, Elissaveta Naumova, Velizar Shivarov, Milena Ivanova

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ivan PavlovLaboratory of Clinical Immunology, Alexandrovska University Hospital, Medical University, 1 Georgi Sofiisky Blvd, 1431, Sofia, Bulgaria.
Evgueniy HadjievDepartment of Clinical Hematology, Alexandrovska University Hospital, Medical University, Sofia, Bulgaria.
Tzvetan AlaikovDepartment of Clinical Hematology, Sofiamed University Hospital, Sofia, Bulgaria.
Sylva SpassovaDepartment of Clinical Hematology, Sofiamed University Hospital, Sofia, Bulgaria.
Angel StoimenovLaboratory of Transfusion Medicine, Sofiamed University Hospital, Sofia, Bulgaria.
Elissaveta NaumovaLaboratory of Clinical Immunology, Alexandrovska University Hospital, Medical University, 1 Georgi Sofiisky Blvd, 1431, Sofia, Bulgaria.
Velizar ShivarovDepartment of Clinical Hematology, Sofiamed University Hospital, Sofia, Bulgaria.ORCID http://orcid.org/0000-0001-5362-7999
Milena IvanovaLaboratory of Clinical Immunology, Alexandrovska University Hospital, Medical University, 1 Georgi Sofiisky Blvd, 1431, Sofia, Bulgaria. mivanova@intech.bg.
Medical University of Sofia · BGAlexandrovska Hospital · BG

Funding

Bulgarian National Science Fund ID_09_157
6 · The paper itself

Abstract

Somatic mutations in JAK2, MPL and CALR are recurrently identified in most of the cases with Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). We applied four molecular genetic methods for identification of CALR exon 9 mutations, including high resolution melt (HRM) analysis, Sanger sequencing, semiconductor target genes sequencing and whole exome sequencing. A total of 78 patients with myeloid malignancies were included in the study. We identified 14 CALR exon 9 mutated cases out of 78 studied patients with myeloid malignancies. All mutated patients were diagnosed with MPN being either PMF (n = 7) or ET (n = 7). Nine cases had type 1 mutations and 5 cases had type 2 mutations. CALR exon 9, MPL exon 10 and JAK2 p. V617F were mutually exclusive. There were no statistically significant differences in the hematological parameters between the cases with CALR and JAK2 or MPL mutations. Notably, all four techniques were fully concordant in the detection of CALR mutations. This is one of the few reports on the CALR mutations frequency in South-eastern populations. Our study shows that the frequency and patterns of these mutations is identical to those in the patients' cohorts from Western countries. Besides we demonstrated the utility of four different methods for their detection.

Indexed as

ExonsMutationAgedBiomarkers, TumorBulgariaCalreticulinFemaleFollow-Up StudiesGenetic TestingHumansJanus Kinase 2MaleMiddle AgedMyeloproliferative DisordersPrognosisBiomarkers, TumorCalreticulinCALR protein, humanJAK2 protein, humanJanus Kinase 2CALRJAK2MPLMPNsMutations

Identifiers

PMID28411309
OpenAlexW2605821804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.